To establish the bioequivalence between riociguat tablet 1.0 mg intended to be marketed (# 502) and riociguat tablet 1.0 mg used for clinical samples (#512) in Japanese healthy adult male subjects
Please see attached Study Results Summary below.
No Inclusion Criteria Available
No Exclusion Criteria Available
Osaka Pharmacology Clinical Research Hospital
Osaka, Japan, 532-0003
E-mail: [email protected]
Phone: Not Available